Compare XBIT & SENS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XBIT | SENS |
|---|---|---|
| Founded | 2005 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Pharmaceuticals and Biotechnology | Industrial Machinery/Components |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 75.0M | 213.2M |
| IPO Year | 2015 | 2014 |
| Metric | XBIT | SENS |
|---|---|---|
| Price | $2.44 | $5.77 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $18.38 |
| AVG Volume (30 Days) | 22.3K | ★ 1.1M |
| Earning Date | 05-08-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $16,389,000.00 |
| Revenue This Year | N/A | $74.15 |
| Revenue Next Year | N/A | $58.60 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 19.85 |
| 52 Week Low | $2.09 | $0.41 |
| 52 Week High | $3.61 | $8.75 |
| Indicator | XBIT | SENS |
|---|---|---|
| Relative Strength Index (RSI) | 49.74 | 45.77 |
| Support Level | $2.15 | $5.26 |
| Resistance Level | $2.49 | $8.55 |
| Average True Range (ATR) | 0.06 | 0.48 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 26.09 | 36.46 |
XBiotech Inc is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies derived from human donors to replicate the human immune response in the treatment of various diseases. It has developed a pipeline of product candidates using True Human antibodies targeting both inflammatory and infectious diseases. The company's developement pipeline comprises: Natrunix, an antibody targeting IL-1a in oncology (pancreatic cancer), a clinical stage therapeutic for Methicillin Resistant Staphylococcus aureus (MRSA), and several pre-clinical stage therapeutics, including: an oral delivery antibody therapeutic for colon infection by C. difficile; an injectable therapy for varicella zoster (adult chicken pox), the causative agent for shingles; and an influenza therapy.
Senseonics Holdings Inc is a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system to improve the lives of people with diabetes by enhancing their ability to manage their disease with relative ease and accuracy. Its implantable CGM system, Eversense, including Eversense E3 and Eversense 365 CGM systems, measures glucose levels via an under-the-skin sensor, a removable and rechargeable smart transmitter, and an app for real-time diabetes monitoring and management. The company operates through one reportable segment which derives its revenues from diabetes products and services and generates the majority of its revenue from the United States.